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Based upon the recent advances in genetic associa-
tion studies, the age of genetically based personalized
medicine may be finally arriving in the near future
for many diseases. The field of hematopoietic cell
transplantation (HCT) is well ahead of this curve. In
the entire field of medicine, there is no better demon-
stration of the power of personalized medicine than
the use of patient-donor histocompatibility antigen
(HLA) matching to improve stem cell transplant
outcomes. Nevertheless, even the HCT field will ben-
efit significantly from the latest developments in
genetic association studies, which has allowed
expanded analyses of the human genome beyond the
major histocompatibility complex (MHC).
Despite extensive efforts using HLA matching to
improve transplant outcomes, the nonrelapse mortal-
ity (NRM) rate has remained relatively unchanged
over the last decade. Recent data from our Center
between 1990 and 2000 indicate that the cumulative
incidence of NRM rate is 25% and 30% for matched
sibling and unrelated myeloablative transplants,
for a hematologic malignancy respectively, (Figure 1).
Althoughmany of these deaths are related to graft-ver-
sus-host disease (GVHD), many are also attributable
to other complications of HCT, including opportunis-
tic infection and organ specific syndromes, some of
which may reflect GVHD and related immune
deficienies. Because there is evidence suggesting that
the risk for some of these complications may be influ-
enced by genetic loci outside of theMHC,many inves-
tigators have already begun to evaluate geneticClinical Research Division and Public Health Sciences
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that play a role in the pathogenesis of these complica-
tion, trying to identify genetic variants that might serve
as a biomarker for not only predicting the risk for
developing these complicated outcomes, but also serve
as potential future therapeutic targets. However, the
results of this approach have been less than impressive.
The majority of studies conducted thus far have
yielded results that are largely still pending rigorous
replication in independent validation studies. This is
likely because of shortcomings related to issues specific
to genetic association studies, such as appropriate
selection of cases and controls, use of biologically
relevant and well-defined phenotypes, adequate sam-
ple size to achieve statistical power, incorporation of
population stratification analysis, and most impor-
tantly, replication of the genetic association in an
independent cohort [1,2].
Our research group recently published 3 studies
evaluating genes in candidate pathways that are
involved in the development of infections and airways
injury after allogeneic HCT. Although these are not
the only studies available, they are representative
examples of genetic association studies using a 2-phase
discovery validation approach. In the first study, we
comprehensively screened innate immunity genes to
discover and verify that single nucleotide polymor-
phism (SNP) haplotypes across the highly polymor-
phic bactericidal permeability increasing (BPI) gene
influences the risk of developing rapid airflow decline
after allogeneic HCT [3]. We subsequently confirmed
that BPI, an anti-inflammatory lipopolysaccaride
binding protein, is produced by small airway
epithelial cells [4], further supporting its potential
role in the development of bronchiolitis obliterans
syndrome, a form of GVHD in the lungs [3]. In a sec-
ond study, we discovered that a SNP haplotype con-
taining a putative functional SNP in the promoter
region of the lipopolysaccharide binding protein
(LBP) gene is associated with a 2-fold increase in risk
of developing Gram-negative bacteremia after alloge-
neic HCT [5]. We then confirmed this association in
a prospective cohort, where we demonstrated that
the homozygous rare genotype is associated with
Figure 1. Cumulative incidence curve for nonrelapse mortality for all
transplants between 1992 and 2005 conducted at the Fred Hutchinson
Cancer Research Center.
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which likely plays a significant role in the downregula-
tion of the innate immune response to Gram-negative
bacteria, potentially resulting in unchecked bacterial
replication [5]. Finally, we recently conducted a study
that comprehensively evaluate toll-like receptors
(TLR) 2, 4, 6, and 9, which discovered and replicated
the finding that a SNP haplotype inTLR4 that contain
previously known functional SNPs is associated with
a 2- to 5-fold increase in risk of developing invasive
aspergillus infection after allogeneic HCT[6].
Despite these and other successes, the candidate
gene approach remains extremely limited in scope
[7]. However the quality of more comprehensive
genetic association studies continues to improve.
The genome-wide genetic association studies pub-
lished in 2007 and 2008 clearly indicate that the field
of genetic epidemiology has entered a new era. These
studies examined complex phenotypes such as diabe-
tes [8,9], rheumatoid arthritis [10,11], and multiple
sclerosis [12] by scanning the genomes of tens of
thousands of individuals using high-throughput
genotyping arrays containing over 500,000 SNPs.
Recently, we also embarked upon a genome-wide
analysis of infectious and organ-specific complica-
tions of allogeneic HCT. Although the stem cell
transplant population is much smaller than those
used for other more common diseases, our population
benefits from phenotypes that occur with higher
frequency and specificity, both of which can signifi-
cantly decrease the false discovery rate and increase
the likelihood that we will discover a genetic
relationship that is biologically plausible. From
3177 patients undergoing allogeneic HCT at our
Center between 1992 and 2005 for whom cryopre-
served peripheral blood mononuclear cells (PBMC)
and/or B-lymphoblastoid cell lines (B-LCL) were
available, we randomly selected a discovery cohort
consisting of 1560 donor-patient pairs (total of 3120
specimens), and reserved the remainder patient/donorpairs as the validation cohort. Each of these speci-
mens was genotyped using the Affymetrix Gene-
Chip Genome-Wide Human SNP Array 5.0,
which contains over 500,000 SNPs placed evenly
across the genome. Population stratification was
accounted for using a principle components approach
to identify a subset of SNPs that capture genetic
differences between ethnic populations.
Some initial results from our analysis of Gram-
negative bacteremia and bronchiolitis obliterans syn-
drome are promising. To develop the Gram-negative
(GN) bacteremia phenotype, an a priori list of GN
bacterial organisms was assembled from a review of
our laboratory database [5]. Patients were considered
a ‘‘case’’ if they had 1 or more positive blood cultures
with 1 of these organisms prior to discharge from
our Center. A time-to-event allelic and genotypic anal-
ysis was performed for each SNP to calculate hazard
ratios and 95% confidence intervals for all allele types
and genotypes respectively. Death was treated as
a competing event. Pretransplant neutropenia, acute
GVHD (aGVHD), and time to engraftment, defined
as 3 consecutive days with a neutrophil count .500
cells/mL, were included as covariates in the genetic
model. Overall, there were 303 cases of GN bacter-
emia in the discovery cohort. After eliminating SNPs
that were identified to be in Hardy-Weinberg disequi-
librium at P \ .001 or had a genotype call rate of
\80%, 17 SNP genotypes in the patient were signifi-
cantly associated with the GN bacteremia phenotype,
with P-values ranging from 1  1026.1 to 1  1028.1
(Figure 2). Using a similar approach for bronchiolitis
obliterans syndrome (BOS), which was defined accord-
ing to recent recommendations from the National
Institutes of Health [13], we have identified 4 patient
and 3 donor genetic loci that are associated with
a higher risk of developing BOS, with P-values ranging
from 1  1026.0 to 1  1028.1.
Despite these promising genetic leads, it should be
recognized that this approach is not without its own
challenges. For instance, when over half a million
analyses are conducted at the same time, the multiple
comparison penalty paid restricts the focus of attention
to the loci that meet the most stringent threshold for
significance. Although this conservative approach
will reduce false positive discoveries, it also means
that promising associations that do not quite meet
the significance threshold will not receive the critical
attention they deserve. Another major limitation of
the agnostic genome-wide approach is that these
discoveries rarely lead to a candidate gene or pathway
whose biologic role is immediately obvious. In fact,
most genome-wide studies thus far have resulted in
associations with loci in gene deserts, leaving scientists
at the beginning of the long and arduous task of
elucidating the mechanisms that account for the
observed associations. Finally, we should recognize
Figure 2. Genome-wide allelic and genotypic association with GN bacteremia for the patient genome. Solid line indicates significance threshold of
1  1026. Circles indicate loci that meet or exceed this significance threshold.
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attractive, environmental influences such as clinical
factors still play a major role in the development of
many of these phenotypes. Our task is to integrate
these genetic discoveries with the critical clinical fac-
tors to develop a biologically plausible hypothesis
that will one day help us improve the outcome of
stem cell transplantation.
As we wait for these discoveries to be validated, we
have already learned 3 valuable lessons regarding the
future of genetic research in HCT. First, although
candidate gene approaches can succeed, they are
less likely to identify genetic variants that will have
a clinically meaningful effect when the entire genome
is considered. However, this does not mean that candi-
date gene approaches should be abandoned. Rather,
we believe that the candidate gene approach should
take advantage of the flood of genetic information
available from genome scans, such that each candidate
gene can be more comprehensively evaluated. Second,
these results demonstrate that an agnostic genome-
wide approach toward transplant outcomes can reveal
highly statistically significant associations. Although
these discoveries still require rigorous validation, it is
inevitable that we have identified leads that will ulti-
mately lead us down a pathway that have never been
previously considered. Importantly, this unbiasedgenome-wide approach will likely identify targets
that are not only clinically meaningful as potential pre-
dictive markers, but will also serve as high-yield thera-
peutic targets. Finally, as we analyze genome-wide
data, we are repeatedly reminded of the importance
of collaboration. Success in genome-wide studies
requires expertise in multiple areas of research (ie,
clinical and genetic epidemiology, statistical genetics,
bioinformatics, molecular biology, immunobiology,
and multiple clinical subspecialties), and is highly
dependent upon cohort size and replication. As a com-
munity of scientists and patients, we are much smaller
than those associated with more common diseases. For
us to fully capitalize upon the coming technological
advances, we will need to pool our resources and
work together collaboratively in this exciting new era
of genome sciences.ACKNOWLEGEMENTS
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